Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of bumetanide on brain function in autism spectrum disorder
IRCT20180901040915N1Phase 2Completed
- Sponsor
- Institute for Cognitive Science Studies
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of bumetanide in Autism Spectrum Disorder (ASD), sponsored by Institute for Cognitive Science Studies. Started Sep 2017; status: completed.
02
Drugs
bumetanide
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on IRCT20180901040915N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180901040915N1.